步长制药上半年净利大幅增长，总裁赵超博士学历、去年薪酬231万元

Core Insights - The company reported a revenue of 5.664 billion yuan for the first half of 2025, representing a year-on-year growth of 4.27% [1][2] - The net profit attributable to shareholders reached 627 million yuan, showing a significant increase of 171.24% compared to the same period last year [1][2] - The net cash flow from operating activities was 959 million yuan, reflecting a growth of 92.87% year-on-year [1][2] Financial Performance - Revenue for the first half of 2025: 5.664 billion yuan, up 4.27% from 5.432 billion yuan in the same period last year [2] - Total profit for the period was approximately 750 million yuan, an increase of 85.55% from around 404 million yuan [2] - Net profit attributable to shareholders: 627 million yuan, up from 231 million yuan, marking a 171.24% increase [2] - Net profit after deducting non-recurring gains and losses: 619 million yuan, up 180.04% from 221 million yuan [2] - Net cash flow from operating activities: 959 million yuan, compared to 497 million yuan last year, a growth of 92.87% [2] Asset and Equity Position - Net assets attributable to shareholders at the end of the reporting period were approximately 10.744 billion yuan, a 5.16% increase from 10.216 billion yuan at the end of the previous year [2] - Total assets amounted to about 19.977 billion yuan, reflecting a 3.35% increase from 19.329 billion yuan [2] Leadership Information - Zhao Chao, the company's president, holds a PhD in economics from Xi'an Jiaotong University and has been in various leadership roles within the company [3] - Zhao Chao's compensation from 2020 to 2024 has been relatively stable, with figures around 231.1 thousand yuan in 2024 [4]